Halozyme Therapeutics (HALO) Non-Current Assets (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Non-Current Assets data on file, last reported at $1.7 billion in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 78.67% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $5.2 billion, a 33.67% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 73.81% from the prior year.
• Non-Current Assets for Q1 2026 stood at $1.7 billion, down from $1.7 billion in the prior quarter.
• Over the last five years, Non-Current Assets for HALO reached as high as $1.7 billion in Q4 2025 and fell as low as $173.6 million in Q1 2022.
• Historically, Non-Current Assets has averaged $1.1 billion across 5 years, with a median of $991.1 million in 2024.
• Across the five-year window, Non-Current Assets soared 4646.49% in 2022 and retreated 16.32% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $1.1 billion in 2022, then retreated by 10.49% to $986.8 million in 2023, then slipped by 0.88% to $978.1 million in 2024, then soared by 73.81% to $1.7 billion in 2025, then declined by 1.79% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $892.5 million in Q3 2025.